Ovagen

Ovagen is commonly described commercially as the tripeptide Glu-Asp-Leu, also indexed as EDL or glutamyl-aspartyl-leucine. Strong PubMed records using the branded name for liver-focused claims were not found, so the defensible package must tie claims to EDL rather than supplier descriptions. Primary indexed studies on EDL include renal cell culture aging experiments and a broader study showing that short fluorescent-labeled peptides can enter HeLa cell nuclei and interact with DNA structures in sequence-dependent ways. These are mechanistic cellular findings, not evidence that Ovagen improves liver function, kidney function, detoxification, metabolism, or aging outcomes in humans.

Renal Cell Aging Models

EDL was studied in aging renal cell cultures and associated with changes in proliferation and markers such as p16, p21, p53, and SIRT6 ^[1].

Signaling Molecule Expression

A related renal cell culture study found that EDL/T-35 influenced MMP-14 and other markers tied to extracellular matrix and cell-renewal biology ^[2].

DNA-Interaction Context

Short labeled peptide studies support a plausible cell-entry and DNA-interaction research mechanism, but not a clinical effect ^[3].

No Defensible Human Dataset

No defensible human clinical safety dataset for Ovagen/EDL was found in the searched primary sources ^[1][2][3].

Claim Limits

Claims about liver repair, detoxification, metabolism, or human anti-aging effects would exceed the evidence ^[1][2].